Green Cross Lab Cell Corporation (144510) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Green Cross Lab Cell Corporation (144510) has a cash flow conversion efficiency ratio of 0.015x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩6.67 Billion ≈ $4.52 Million USD) by net assets (₩431.56 Billion ≈ $292.46 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Green Cross Lab Cell Corporation balance sheet quality to measure how much of total assets are equity-financed.
Green Cross Lab Cell Corporation - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Green Cross Lab Cell Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Green Cross Lab Cell Corporation (144510) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Green Cross Lab Cell Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Green Cross Lab Cell Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
China Automotive Systems Inc
NASDAQ:CAAS
|
0.069x |
|
Sang-A Frontec Co.Ltd
KQ:089980
|
0.031x |
|
Renaissance Global Limited
NSE:RGL
|
-0.053x |
|
Seven West Media Ltd
AU:SWM
|
-0.001x |
|
Paik Kwang Ind
KO:001340
|
0.021x |
|
Journey Medical Corp
NASDAQ:DERM
|
-0.200x |
|
Globe Union Industrial Corp
TW:9934
|
0.044x |
|
Red Planet Indonesia Tbk
JK:PSKT
|
0.006x |
Annual Cash Flow Conversion Efficiency for Green Cross Lab Cell Corporation (2015–2024)
The table below shows the annual cash flow conversion efficiency of Green Cross Lab Cell Corporation from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see Green Cross Lab Cell Corporation (144510) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩457.79 Billion ≈ $310.24 Million |
₩11.34 Billion ≈ $7.69 Million |
0.025x | +265.48% |
| 2023-12-31 | ₩541.48 Billion ≈ $366.95 Million |
₩3.67 Billion ≈ $2.49 Million |
0.007x | -94.50% |
| 2022-12-31 | ₩538.46 Billion ≈ $364.91 Million |
₩66.42 Billion ≈ $45.01 Million |
0.123x | +163.63% |
| 2021-12-31 | ₩511.00 Billion ≈ $346.30 Million |
₩23.91 Billion ≈ $16.20 Million |
0.047x | -75.73% |
| 2020-12-31 | ₩47.17 Billion ≈ $31.97 Million |
₩9.09 Billion ≈ $6.16 Million |
0.193x | +3707.58% |
| 2019-12-31 | ₩44.05 Billion ≈ $29.85 Million |
₩223.04 Million ≈ $151.15K |
0.005x | -50.78% |
| 2018-12-31 | ₩47.72 Billion ≈ $32.34 Million |
₩490.92 Million ≈ $332.69K |
0.010x | -82.63% |
| 2017-12-31 | ₩48.32 Billion ≈ $32.75 Million |
₩2.86 Billion ≈ $1.94 Million |
0.059x | +1059.97% |
| 2016-12-31 | ₩48.10 Billion ≈ $32.59 Million |
₩-296.65 Million ≈ $-201.04K |
-0.006x | -103.71% |
| 2015-12-31 | ₩8.96 Billion ≈ $6.07 Million |
₩1.49 Billion ≈ $1.01 Million |
0.166x | -- |
About Green Cross Lab Cell Corporation
GC Cell Corporation develops cell therapy products. It also provides cell banking, sample inspection, clinical trial, and bio logistics services. Its main product is Immuncell-LC. GC Cell Corporation has strategic agreement with Lukas Biomedical Co., Ltd. to develop Cell therapy. The company was formerly known as Green Cross Lab Cell Corporation and changed its name to GC Cell Corporation in Nove… Read more